Molecular Diagnostics
Europe · 3 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Europe Genetic Testing Market Industry Trends and Forecast to 2034: Segmented by (Type, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$5.86 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $3.86 Bn | — | — |
| 2025 (base) | $4.25 Bn | +$390.3 Mn | — |
| 2026 (forecast) | $4.68 Bn | +$429.7 Mn | +10.1% |
| 2027 (forecast) | $5.16 Bn | +$473.1 Mn | +21.2% |
| 2028 (forecast) | $5.68 Bn | +$520.9 Mn | +33.5% |
| 2029 (forecast) | $6.25 Bn | +$573.5 Mn | +46.9% |
| 2030 (forecast) | $6.88 Bn | +$631.4 Mn | +61.8% |
| 2031 (forecast) | $7.58 Bn | +$695.2 Mn | +78.1% |
| 2032 (forecast) | $8.34 Bn | +$765.4 Mn | +96.1% |
| 2033 (forecast) | $9.19 Bn | +$842.7 Mn | +115.9% |
| 2034 (forecast) | $10.11 Bn | +$927.8 Mn | +137.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $4.25 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $10.11 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 10.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, technology and end user (see all) |
| Key players | Myriad Genetics, Inc., Illumina, Inc., Natera, Invitae, Quest Diagnostics and 1 more (see all) |
| Regulator in Europe | EU MDRSource: European Commission, medical devices. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Genetic testing reads a person's DNA to find inherited conditions, cancer risk, drug response and family links.
Key segments of the genetic testing market include type (Predictive Testing, Carrier Testing and Diagnostic Testing) and technology (PCR, Sequencing and Microarrays).
Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the genetic testing market.
Automation, smaller and cheaper instruments and growth in cancer and genetic testing give the genetic testing market room to grow.
Costly instruments, a shortage of skilled lab staff and uneven payment for new tests hold back the genetic testing market.
The genetic testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.[1] In the countries we cover here, medical devices are regulated by ANSM (France)[2], BfArM (Germany)[3], Ministry of Health (Italy)[4], Roszdravnadzor (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], IGJ (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15]
[1] European Commission, medical devices. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Ministry of Health. Checked 14 Nov 2026.
[5] Roszdravnadzor. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] Health and Youth Care Inspectorate (IGJ). Checked 19 Nov 2026.
[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.
[10] Swissmedic. Checked 19 Nov 2026.
[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.
[12] Danish Medicines Agency. Checked 19 Nov 2026.
[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.
[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.
[15] European Commission, health technology assessment. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how genetic testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.
From our blog
Europe · 3 shared keywords
Europe · 2 shared keywords
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe
Pharmaceuticals · Europe
Digital Health · Europe
Healthcare Services · Europe
Healthcare Services · Europe
Digital Health · Europe
Healthcare Services · Europe